- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04242836
Development and Validation of a Digital Optotype for Near Vision in Greek Language. (DeDART)
Development and Validation of a Computer-based Digital Near-vision Optotype Based on the Greek Version of the Print MNREAD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Present study aims to develop and validate a computer-based digital near-vision optotype based on the Greek version of the print MNREAD.
Specifically, it aims to evaluate the level of agreement between the conventional printed greek MNREAD chart and the corresponding digital chart, as well as test-retest reliability of the digital optotype.
To address these aims, four reading parameters measured with the print and the digital version are compared. These parameters are the following:
- Reading Acuity (RA)
- Maximum Reading Speed (MRS)
- Critical Print Size (CPS)
- Accessibility Index (ACC)
All the comparisons take place in two groups: a) a Normal Vision Group (NVG), and b) a Low Vision Group (LVG) in order to estimate the reading capacity in a population with a wide range of vision.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Evros
-
Alexandroupolis, Evros, Greece, 68100
- University Hospital of Alexandroupolis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- adequate literacy of written Greek language
Exclusion Criteria:
- dyslexia
- attention-deficiency
- former diagnosis of mental diseases
- former diagnosis of psychiatric diseases
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Control group
These patients are tested on the printed Greek MNREAD |
One randomly selected eye is included for each study participant.
Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance.
All four parameters (RA, MRS, CPS and ACC) are evaluated.
|
Study group
The same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
|
One randomly selected eye is included for each study participant.
Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance.
All four parameters (RA, MRS, CPS and ACC) are evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reading Acuity (RA)
Time Frame: through study completion, an average of 8 months
|
The smallest print that the patient can read without making significant errors, and can be calculated by the following formula: Acuity (in logMAR)= 1.4 - (sentences x 0.1) + (errors x 0.01). |
through study completion, an average of 8 months
|
Maximum Reading Speed (MRS)
Time Frame: through study completion, an average of 8 months
|
The patient's reading speed when reading is not limited by print size , and is calculated by averaging the speed of the sentences with print size larger than the CPS.
[(in words per minute (wpm)]
|
through study completion, an average of 8 months
|
Critical Print Size (CPS)
Time Frame: through study completion, an average of 8 months
|
The smallest print size at which patients can read with their MRS, and is identified as the print size of the sentence fulfilling this criterion: all of the following sentences are read at a speed that is 1.96 times the standard deviation below the average of the larger preceding sentences (that is the MRS).
In other words, it is defined as the smallest print size that yields 90% of the MRS [(in logMAR)]
|
through study completion, an average of 8 months
|
Accessibility Index (ACC)
Time Frame: through study completion, an average of 8 months
|
The mean reading speed measured across the 10 largest print sizes (1.3 to 0.4 logMAR) of the MNREAD Acuity Chart at 40 cm normalized by 200 wpm, which was the mean value for a group of 365 normally sighted young adults aged 18 to 39 years old.
|
through study completion, an average of 8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraclass Correlation Coefficients (ICCs) for study participants
Time Frame: through study completion, an average of 8 months
|
Level of agreement between the print and the digital version are evaluated by calculation of the ICCs for the 4 reading parameters (RA, MRS, CPS, ACC).
|
through study completion, an average of 8 months
|
Test-retest Intraclass Correlation Coefficients (ICCs)
Time Frame: through study completion, an average of 8 months
|
Test-retest reliability of the digital optotype is evaluated by ICCs for the 4 reading parameters (RA, MRS, CPS, ACC)..
|
through study completion, an average of 8 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Georgios Labiris, MD, PhD, University Hospital of Alexandroupolis, Alexandroupolis, Greece
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ES3/Th2/27-03-2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
Lee, Steven, M.D.CompletedMyopia, | Hyperopia, | Astigmatism, | Presbyopia, | Eye Strain,
-
Allotex, Inc.RecruitingPresbyopiaCzechia, Ireland, Turkey, United Kingdom
-
Coopervision, Inc.Centre for Ocular Research & Education, CanadaRecruitingPresbyopiaUnited States, Canada
-
Optall VisionRecruiting
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncCompleted
-
Allotex, Inc.TerminatedPresbyopiaBelgium, Ireland, United Kingdom
-
Coopervision, Inc.CORECompletedPresbyopiaUnited States, Canada
Clinical Trials on MNREAD testing
-
The Hospital for Sick ChildrenCompleted
-
Democritus University of ThraceUniversity of ThessalyRecruitingRefractive Errors | Vision Disorders | Low VisionGreece
-
Hamilton Health Sciences CorporationRecruiting
-
Democritus University of ThraceUniversity of ThessalyCompletedRefractive Errors | Presbyopia | Low Vision | Near Vision | ReadingGreece
-
Allegheny Singer Research Institute (also known...Active, not recruitingEpithelial Ovarian CancerUnited States
-
Vanderbilt University Medical CenterRecruitingPostural Orthostatic Tachycardia Syndrome | Acute Hepatic PorphyriaUnited States
-
Johns Hopkins Bloomberg School of Public HealthNational Institute on Drug Abuse (NIDA)Completed
-
University of MichiganCompletedBladder Pain and Discomfort | Urinary Urgency and Frequency | Bothersome SymptomsUnited States
-
Royal Devon and Exeter NHS Foundation TrustNot yet recruitingHIV Infections | Syphilis Infection | Hepatitis B and Hepatitis CUnited Kingdom